This inventor holds 14 USPTO granted patents and 4 published patent applications, plus 1 CIPO patent and 2 EPO patents. Top assignees: Bach Biosciences, LLC, Tufts University. Active years: 2007-2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2007-2024
Title: The Innovations of David George Sanford
Introduction
David George Sanford is a prominent inventor based in Reading, Massachusetts. With an impressive portfolio of 14 patents, Sanford has made significant contributions to the field of medical therapeutics, particularly in targeted drug delivery systems.
Latest Patents
Among his latest innovations is a patent titled "FAP-activated therapeutic agents, and uses related thereto." This patent details the development of prodrugs of cytotoxic anthracyclines, including doxorubicin, which are specifically cleaved and activated by fibroblast activating protein (FAP). These prodrugs aim to enhance the targeted delivery of cytotoxic agents to tissues that express FAP, notably in various cancers and conditions such as fibrosis and inflammation. In addition to this, Sanford has provided methods for using these prodrugs in therapeutic settings, showcasing his commitment to advancing cancer treatment.
Career Highlights
Throughout his career, David George Sanford has collaborated with notable institutions such as Bach Biosciences, LLC and Tufts College. His innovative work has bolstered advancements in the medical field, particularly in cancer therapeutics, through his focused research on drug design and development.
Collaborations
Sanford’s collaborative efforts include working alongside esteemed colleagues, including William W. Bachovchin and Hung-sen Lai. Together, they have explored cutting-edge solutions to address critical medical challenges, fostering innovation in their respective fields.
Conclusion
In conclusion, David George Sanford stands out as a dedicated inventor whose work in FAP-activated therapeutic agents represents a significant leap in the medical innovation landscape. His extensive patent portfolio and partnerships with leading organizations underscore his influence and commitment to improving health outcomes. As research in targeted therapies continues to evolve, Sanford's contributions remain vital to the advancement of cancer treatment and beyond.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile